Cagrilintide Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 1 explicitly reviewed source snapshot.
Append-only review history
Human Evidence Review changes
Follow approved review versions and source-published notices without confusing provider dates with PeptideScanner review dates.
Approved publication history
Review versions
Exenatide Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
- PubMed · 28910237 · Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes ↗
- PubMed · 18803987 · Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study ↗
Leuprolide Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
Liraglutide Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
Octreotide Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
- PubMed · 2229278 · Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects ↗
- PubMed · 34953531 · Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial ↗
Setmelanotide Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
- PubMed · 33137293 · Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials ↗
- PubMed · 36356613 · Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period ↗
Survodutide Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
Teriparatide Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
- PubMed · 11346808 · Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis ↗
- PubMed · 29129436 · Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial ↗
Tesamorelin Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
Tirzepatide Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
BPC-157 Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 3 explicitly reviewed source snapshots.
3 reviewed citations
Retatrutide Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
2 reviewed citations
- PubMed · 37366315 · Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial ↗
- PubMed · 37385280 · Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA ↗
Semaglutide Human Evidence Review version 1
PeptideScanner published bounded review version 1 from 2 explicitly reviewed source snapshots.
Source-published notices
Publisher notices connected to reviews
Erratum connected to the Octreotide review
The reviewed Crossref snapshot attributes this erratum notice to publisher metadata. It is not a PeptideScanner correction.
- PubMed · 34953531 · Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial ↗
- Crossref · 10.1016/s2213-8587(21)00296-5 · Crossref integrity metadata for PMID 34953531 ↗
- DOI · 10.1016/s2213-8587(22)00051-1 · Erratum ↗
Erratum connected to the Setmelanotide review
The reviewed Crossref snapshot attributes this erratum notice to publisher metadata. It is not a PeptideScanner correction.
- PubMed · 36356613 · Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period ↗
- Crossref · 10.1016/s2213-8587(22)00277-7 · Crossref integrity metadata for PMID 36356613 ↗
- DOI · 10.1016/s2213-8587(22)00360-6 · Erratum ↗
Erratum connected to the Survodutide review
The reviewed Crossref snapshot attributes this erratum notice to publisher metadata. It is not a PeptideScanner correction.
Erratum connected to the Tirzepatide review
The reviewed Crossref snapshot attributes this erratum notice to publisher metadata. It is not a PeptideScanner correction.
- PubMed · 34186022 · Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial ↗
- Crossref · 10.1016/s0140-6736(21)01324-6 · Crossref integrity metadata for PMID 34186022 ↗
- DOI · 10.1016/s0140-6736(21)01556-7 · Erratum ↗